載入中
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
前收盤價
US$3.90
−US$0.07 · -1.76%
盤中時間採用ET。市場資料可能有所延遲。
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
日內區間
目前US$3.90
52週區間
目前US$3.90
盤中時間採用ET。市場資料可能有所延遲。
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
日內區間
目前US$3.90
52週區間
目前US$3.90
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | 564 USD | — | — |
| 毛利 | — | — | −564 USD | — | — |
| 研究與開發 | 261.97萬 USD | 322.92萬 USD | 126.71萬 USD | 195.03萬 USD | 839.56萬 USD |
| 銷售、一般及管理費用 | 517.98萬 USD | 505.52萬 USD | 562.09萬 USD | 890.92萬 USD | 934.47萬 USD |
| 營業費用 | 779.95萬 USD | 828.45萬 USD | 688.74萬 USD | 1085.95萬 USD | 1928.87萬 USD |
| 利息收入 | 14.96萬 USD | 17.87萬 USD | 6.98萬 USD | 6.33萬 USD | 6539 USD |
| 折舊和攤銷 | 565 USD | 565 USD | 564 USD | 564 USD | 5.51萬 USD |
| 營業利益 | −779.95萬 USD | −828.45萬 USD | −688.79萬 USD | −1085.95萬 USD | −1928.87萬 USD |
| 淨利 | −797.72萬 USD | −1319.75萬 USD | −700.19萬 USD | −1273.14萬 USD | −1942.33萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.50
上漲空間 117.95%評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年2月6日 | 1:25 | — | — |
股票分割 | 2023年8月7日 | 1:25 | — | — |
已生效 2026年2月6日
1:25
已生效 2023年8月7日
1:25
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
